Mutation detail:
| Mutation site | A150V |
| Virus | Human rhinovirus |
Mutation level  |
Amino acid level |
| Gene/protein/region type | VP1 |
| Gene ID | 1461213 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | B |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | NC_001490.1 |
| Drug/antibody/vaccine | ca603 resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Capsid Protein VP1 |
| Uniprot protein ID | P03303 |
| Protein length | 289 amino acids |
| Protein description | VP1 forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host ICAM1 to provide virion attachment to target host cells. |
Literature information:
| Pubmed ID | 26169596 |
| Clinical information | No |
| Disease | - |
| Published year | 2015 |
| Journal | Virology Journal |
| Title | In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses |
| Author | Celine Lacroix,Samuela Laconi,Fabrizio Angius,Antonio Coluccia,Romano Silvestri |
| Evidence | The single mutant HRV14IC VP1_A150V proved to be 10-and 40-fold less sensitive to ca603 and pleconaril, respectively (Table 2). Both ca603 and pleconaril proved also markely less active (12-and 28-fold, respectively) against the double mutant HRV14ICVP1_A |